Ustekinumab (90 mg) — Competitive Intelligence Brief

Ustekinumab (90 mg) (Ustekinumab (90 mg)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-12/23 inhibitor. Area: Immunology.

phase 3 IL-12/23 inhibitor p40 subunit of IL-12 and IL-23 Immunology Biologic

Target snapshot

Ustekinumab (90 mg) (Ustekinumab (90 mg)) — Janssen Scientific Affairs, LLC. Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ustekinumab (90 mg) TARGET	Ustekinumab (90 mg)	Janssen Scientific Affairs, LLC	phase 3	IL-12/23 inhibitor	p40 subunit of IL-12 and IL-23
Ustekinumab - Standard Dosage	Ustekinumab - Standard Dosage	Humanitas Clinical and Research Center	phase 3	IL-12/23 inhibitor	p40 subunit of IL-12 and IL-23
Ustekinumab - Half-Standard Dosage	Ustekinumab - Half-Standard Dosage	Janssen Research & Development, LLC	phase 3	IL-12/23 inhibitor	p40 subunit of IL-12 and IL-23

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-12/23 inhibitor class)

1. Humanitas Clinical and Research Center · 1 drug in this class
2. Janssen Research & Development, LLC · 1 drug in this class
3. Janssen Scientific Affairs, LLC · 1 drug in this class